Ross Morton
Managing Partner
Expertise: Diligence & Financing
Ross founded Nodenza and leads the Fund in identifying new investment opportunities, engaging with Limited Partners and day to day operations. He sits on the Investment Committee.
Ross was COO of Akaza Bioscience, sold to Aquarious Bio in 2022. Prior, he was on the management team of Izana Bioscience, which sold to one of the Roivant companies in 2020.
Previously, Ross was a management consultant in the Advisory practice at Kinapse, a Syneos company supporting Big Pharma R&D projects.
Bryan Morton Chairman & Partner
Expertise: Diligence & Financing
Bryan is responsible for providing commercial expertise in evaluating potential & ongoing investments, as well as deal terms and negotiation strategy. He sits on the Investment Committee.
Previously the CEO and then Chairman of EUSA Pharma, CEO of Zeneus Pharma, and Chairman of Aircraft Medical, Bryan has a broad experience in development & commercial stage biotech & medical device companies.
He held senior management positions at Merck & Bristol Myers Squibb.
Our Team
Dr Tim Corn Partner
Expertise: Clinical & Regulatory
Tim oversees the Clinical & Regulatory needs of our investments. He sits on the Investment Committee.
A serial CMO, Tim has led the development, regulatory approval, and launch of 20+ products with the FDA and EMA.
Tim was the Chief Medical Officer at the highly successful Zeneus Pharma and EUSA Pharma. He now holds various industry Board seats.
He previously held positions at GSK, Elan, Jazz & the UK Medicines and Healthcare products Regulatory Agency.
Dr Dev Kumar Partner
Expertise: Market Access & Intellectual Property
Dev leads the Legal & Intellectual Property needs of portfolio companies. An expert in guiding the transaction and commercial aspects of investments, Dev sits on the Investment Committee.
Dev is dually qualified as a lawyer & medical doctor. He focuses on corporate, regulatory, and IP matters with a specialist interest in pricing & reimbursement.
Most recently General Counsel of EUSA Pharma, Dev now sits on various Boards.
He previously held positions at Biogen, UCB, Boehringer Ingelheim, & the University of Oxford.
Dr Gary Whale Partner
Expertise: CMC & Product Launch
Gary spearheads the Chemistry, Manufacturing, & Control function and is a due diligence powerhouse. He sits on the Investment Committee.
Gary has deep industry experience in biotech & pharma. He is currently the CTO at Zura Bio, and has held senior management positions at EUSA Pharma, Vhsquared, & Emergent Biosolutions.
Previous technical roles include Microscience and Procter & Gamble, giving him extensive knowledge of all aspects of drug development, manufacturing & commercial launch.